User profiles for Nigel S. Paneth

Nigel Paneth

Professor of Epidemiology, Michigan State University
Verified email at msu.edu
Cited by 42259

[HTML][HTML] Early safety indicators of COVID-19 convalescent plasma in 5000 patients

…, JL Winters, JR Stubbs, NS Paneth… - The Journal of …, 2020 - Am Soc Clin Investig
BACKGROUND Convalescent plasma is the only antibody-based therapy currently available
for patients with coronavirus disease 2019 (COVID-19). It has robust historical precedence …

Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients

…, BP Butterfield, MA Sexton, JCD Soto, NS Paneth… - Mayo Clinic …, 2020 - Elsevier
Objective To provide an update on key safety metrics after transfusion of convalescent plasma
in hospitalized coronavirus 2019 (COVID-19) patients, having previously demonstrated …

The problem of low birth weight

NS Paneth - The future of children, 1995 - JSTOR
Low birth weight is a major public health problem in the United States, contributing substantially
both to infant mortality and to childhood handicap. The principal determinant of low birth …

[HTML][HTML] Convalescent plasma antibody levels and the risk of death from Covid-19

…, PR Bauer, JE Blair, NS Paneth… - … England Journal of …, 2021 - Mass Medical Soc
Background Convalescent plasma has been widely used to treat coronavirus disease 2019 (Covid-19)
under the presumption that such plasma contains potentially therapeutic …

Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience

…, SE Baker, JRA Shepherd, N van Helmond, NS Paneth… - medrxiv, 2020 - medrxiv.org
Importance Passive antibody transfer is a longstanding treatment strategy for infectious
diseases that involve the respiratory system. In this context, human convalescent plasma has …

[HTML][HTML] The effect of convalescent plasma therapy on mortality among patients with COVID-19: systematic review and meta-analysis

…, DL Fairweather, KA Bruno, Z Wang, NS Paneth… - Mayo Clinic …, 2021 - Elsevier
To determine the effect of COVID-19 convalescent plasma on mortality, we aggregated
patient outcome data from 10 randomized clinical trials, 20 matched control studies, 2 dose-…

Neonatal cranial ultrasound abnormalities in low birth weight infants: relation to cognitive outcomes at six years of age

…, C Torre, SR Blumenthal, NS Paneth - …, 1996 - publications.aap.org
Objective. To assess the independent relation of neonatal cranial ultrasound (US)
abnormalities in low birth weight (LBW) infants to cognitive outcomes at 6 years of age. Design. …

Use of convalescent plasma in COVID‐19 patients with immunosuppression

…, DL Fairweather, KA Bruno, NS Paneth… - …, 2021 - Wiley Online Library
In the absence of effective countermeasures, human convalescent plasma has been widely
used to treat severe acute respiratory syndrome coronavirus 2, the causative agent of novel …

[HTML][HTML] Convalescent plasma therapy for COVID-19: a graphical mosaic of the worldwide evidence

…, RS Wright, DL Fairweather, NS Paneth… - Frontiers in …, 2021 - frontiersin.org
Convalescent plasma has been used worldwide to treat patients hospitalized with coronavirus
disease 2019 (COVID-19) and prevent disease progression. Despite global usage, …

[HTML][HTML] Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study

…, JR Stubbs, JL Winters, A Casadevall, NS Paneth… - PLoS …, 2021 - journals.plos.org
Background The United States (US) Expanded Access Program (EAP) to coronavirus disease
2019 (COVID-19) convalescent plasma was initiated in response to the rapid spread of …